ライフサイエンスコーパス: difluoromethylornithine

1 e and enhances tumour polyamine depletion by difluoromethylornithine.

2 ment in cells grown in the presence of alpha-difluoromethylornithine.

3 re potent inhibitor of the enzyme than alpha-difluoromethylornithine.

4 xogenous putrescine in the presence of alpha-difluoromethylornithine.

5 y preventing putrescine formation with alpha-difluoromethylornithine.

6 on of Xenopus oocytes injected with 50 nl of difluoromethylornithine (5 mM) and methylglyoxal bis(gua

7 ivation is polyamine dependent because alpha-difluoromethylornithine, a specific inhibitor of ODC act

8 However, the addition of difluoromethylornithine, a specific ODC inhibitor, to th

9 Treatment with alpha-difluoromethylornithine, a specific ornithine decarboxyl

10 Furthermore, alpha-difluoromethylornithine, a suicide inhibitor of ODC, inh

11 The specific ODC inhibitor, alpha-difluoromethylornithine, abrogated all suppressive effec

12 dition, in vivo inhibition of ODC with alpha-difluoromethylornithine also exacerbated the colitis.

13 and responded to anti-GD2 immunotherapy and difluoromethylornithine, an FDA-approved inhibitor targe

14 Treatment of gerbils with either alpha-difluoromethylornithine, an inhibitor of ODC, or MDL 725

15 depletion of cellular polyamines with alpha-difluoromethylornithine, an inhibitor of ornithine decar

16 Treatment of ZD:Wt mice with alpha-difluoromethylornithine, an inhibitor of ornithine decar

17 alpha-Difluoromethylornithine, an irreversible inhibitor of OD

18 Oral consumption of alpha-difluoromethylornithine, an irreversible specific inhibi

19 rrest induced by a 72 h treatment with alpha-difluoromethylornithine, an ornithine decarboxylase (ODC

20 f cationic amino acid transport, or by alpha-difluoromethylornithine, an ornithine decarboxylase inhi

21 lbenzylamine and two chemopreventive agents, difluoromethylornithine and perillyl alcohol.

22 ine was inhibited by the ODC inhibitor alpha-difluoromethylornithine, and L-proline generation was bl

23 2-Difluoromethylornithine could also reactivate hair growt

24 The ODC inhibitor 2-difluoromethylornithine could prevent hair loss and part

25 Inhibiting ODC activity with alpha-difluoromethylornithine delayed DCVC-induced cell death.

26 Because the ODC inhibitor difluoromethylornithine (DFMO) acts like RS1-Reg(S20E),

27 intracellular polyamine synthesis with alpha-difluoromethylornithine (DFMO) also increased MitoROS an

28 Two compounds, difluoromethylornithine (DFMO) and 5-fluorouracil (5-FU)

29 We studied effects of the combination of difluoromethylornithine (DFMO) and sulindac on biomarker

30 DL-alpha-Difluoromethylornithine (DFMO) causes polyamines of the

31 toma (NB) cells with the ODC inhibitor alpha-difluoromethylornithine (DFMO) depleted polyamine pools

32 ibition of polyamine biosynthesis with alpha-difluoromethylornithine (DFMO) has been shown to inhibit

33 gulation of ODC1 or direct ODC inhibition by difluoromethylornithine (DFMO) increased efficacy of SPA

34 Depletion of cellular polyamines by DL-alpha-difluoromethylornithine (DFMO) induced levels of JunD mR

35 The Odc inhibitor alpha-difluoromethylornithine (DFMO) inhibited neuroblast prol

36 Alpha-difluoromethylornithine (DFMO) inhibits the proto-oncoge

37 L-Alpha-difluoromethylornithine (DFMO) is a chemopreventive agen

38 sms underlying the chemopreventive effect of difluoromethylornithine (DFMO) on the development of mam

39 eatment with the Odc suicide inhibitor alpha-difluoromethylornithine (DFMO) or Odc heterozygosity mar

40 We found that the inhibition of ODC by alpha-difluoromethylornithine (DFMO) resulted in a approximate

41 Treatment with the ODC inhibitor difluoromethylornithine (DFMO) sensitized TNBC cells to

42 ty by RS1-Reg mutants and the ODC1 inhibitor difluoromethylornithine (DFMO) was measured in the absen

43 Administration of difluoromethylornithine (DFMO), a clinically approved in

44 tion of the NO donor agents as well as alpha-difluoromethylornithine (DFMO), a known ODC inhibitor, w

45 of ODC/Ras double transgenic mice with alpha-difluoromethylornithine (DFMO), a specific inhibitor of

46 When K14-MEK mice were given alpha-difluoromethylornithine (DFMO), a suicide inactivator of

47 ificantly higher potency in vitro than alpha-difluoromethylornithine (DFMO), a U.S. Food and Drug Adm

48 etermine the chemopreventive effect of alpha-difluoromethylornithine (DFMO), an enzyme-activated irre

49 by zinc deficiency can be inhibited by alpha-difluoromethylornithine (DFMO), an enzyme-activated, irr

50 amine levels in COS-7 cells induced by alpha-difluoromethylornithine (DFMO), an inhibitor of ornithin

51 cultured in the presence or absence of alpha-difluoromethylornithine (DFMO), an inhibitor of the poly

52 We administered alpha-difluoromethylornithine (DFMO), an irreversible inhibito

53 We administered alpha-difluoromethylornithine (DFMO), an irreversible inhibito

54 The use of alpha-difluoromethylornithine (DFMO), an irreversible inhibito

55 f cationic amino acid transport, or by alpha-difluoromethylornithine (DFMO), an ODC inhibitor.

56 , we hypothesized that the addition of alpha-difluoromethylornithine (DFMO), an ornithine decarboxyla

57 thout the ornithine decarboxylase inhibitor, difluoromethylornithine (DFMO), and induced to undergo a

58 lls were exposed to the specific ODC blocker difluoromethylornithine (DFMO), and ODC activity, intrac

59 the ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO), beginning at the time th

60 N1,N11-diethylnorspermine (DENSPM) or alpha-difluoromethylornithine (DFMO), have synergistic effects

61 s of polyamine biosynthesis, including alpha-difluoromethylornithine (DFMO), inhibit tumor growth, bu

62 NO, like alpha-difluoromethylornithine (DFMO), interferes with cell pro

63 One of the currently used drugs, alpha-difluoromethylornithine (DFMO), is a suicide inhibitor o

64 that the cancer chemopreventive agent alpha-difluoromethylornithine (DFMO), known to inhibit the enz

65 (2) In combination with difluoromethylornithine (DFMO), P-S reduced tumor multip

66 on with the polyamine biosynthesis inhibitor difluoromethylornithine (DFMO), provides a method to tar

67 A specific inhibitor of the transgene, alpha-difluoromethylornithine (DFMO), reversibly blocked the a

68 PA, the irreversible inhibitor of ODC, alpha-difluoromethylornithine (DFMO), was used.

69 the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO).

70 tors N-hydroxy-nor-L-arginine (nor-NOHA) and difluoromethylornithine (DFMO).

71 e alone, dehydroepiandrosterone (DHEA), or 2-difluoromethylornithine (DFMO).

72 the ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO).

73 molecules that potentiate the ODC inhibitor, difluoromethylornithine (DFMO).

74 mine synthesis, is irreversibly inhibited by difluoromethylornithine (DFMO).

75 ration of the suicide inhibitor of ODC alpha-difluoromethylornithine (DFMO, 0.5% w/v) in the drinking

76 f two molecules that alter polyamine levels: difluoromethylornithine (DFMO; also called eflornithine)

77 orrelated in diabetic and control rats given difluoromethylornithine (DFMO; Marion Merrell Dow, Cinci

78 ention with the ODC inhibitor, eflornithine (difluoromethylornithine; DFMO).

79 nhibiting ornithine decarboxylase with alpha-difluoromethylornithine dramatically enhanced the cytopl

80 atment with the biosynthesis inhibitor alpha-difluoromethylornithine during tetracycline removal inte

81 and the pharmacological agents piroxicam and difluoromethylornithine each reduced intestinal adenoma

82 Arginase inhibitor alpha-difluoromethylornithine enhanced NO production/dilation

83 as, whereas the combination of piroxicam and difluoromethylornithine exerted a moderate effect.

84 al polyamine biosynthesis, and the inhibitor difluoromethylornithine has shown clinical activity(5).

85 on to that observed for putrescine and alpha-difluoromethylornithine in previous T. brucei ODC struct

86 ing ornithine decarboxylase (ODC) with alpha-difluoromethylornithine increased the levels of ATF-2 mR

87 Depletion of cellular polyamines by alpha-difluoromethylornithine induced levels of phosphorylated

88 Polyamine depletion with alpha-difluoromethylornithine inhibited the activities of RhoA

89 , the polyamine biosynthesis inhibitor alpha-difluoromethylornithine inhibits the ability of MTAP-def

90 the ornithine decarboxylase inhibitor alpha-difluoromethylornithine or the S-adenosylmethionine deca

91 ed either apoptosis in the basal epithelium (difluoromethylornithine) or both apoptosis and vacuolati

92 ated with the polyamine synthesis inhibitor, difluoromethylornithine, or the K(ATP) channel inhibitor

93 well as those grown in the presence of alpha-difluoromethylornithine plus putrescine.

94 Inhibition of ODC by difluoromethylornithine prevented basal and induced cell

95 stration of the suicidal ODC inhibitor alpha-difluoromethylornithine reduced UVB-induced BCCs in Ptch

96 interfering RNA or the competitive inhibitor difluoromethylornithine restored iNOS protein expression

97 he ornithine decarboxylase inhibitor L-alpha-difluoromethylornithine sensitized all of these leukemia

98 ptosis could be blocked by the ODC inhibitor difluoromethylornithine, the caspase inhibitors Z-VAD FM

99 m target of Akt, was also increased in alpha-difluoromethylornithine-treated cells, which was prevent

100 alpha-Difluoromethylornithine treatment of infected mice resto

101 vities in J774.1 cells using L-norvaline and difluoromethylornithine treatment, respectively.

102 The ODC inhibitor, alpha-difluoromethylornithine, was administered to H pylori-in

103 The "resurrection drug" eflornithine (difluoromethylornithine), which is used clinically to tr

104 reatment with the ODC enzyme inhibitor alpha-difluoromethylornithine, which results in regression of